Innovent Biologics Technology Limited (shanghai R&d Center)

This early-stage trial tests the safety of a new oral drug, IBI3032, in 104 people. Part A gives a single dose to healthy volunteers, while Part B gives multiple doses over 4 weeks to people with overweight or obesity. The goal is to check for side effects and how the drug moves …

This Phase 3 trial tests whether a new drug, tigulixostat, is better than the standard gout medication febuxostat at lowering uric acid levels in Chinese adults with gout. About 600 participants will take one of the two drugs for 24 weeks, then switch to tigulixostat for another …

This early-phase study tests a new drug called IBI3026 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and check for side effects. About 300 participants will take part across multiple centers.

This study tests a new drug called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent further vision decline over 52 weeks. About 800 adults aged 50 and older with act…